Linkage between Increased Nociception and Olfaction via a SCN9A Haplotype

Dirk Heimann1, Jörn Lötsch1,2*, Thomas Hummel3, Alexandra Doehring1, Bruno G. Oertel1,2

1 Institute of Clinical Pharmacology, Goethe - University, Frankfurt am Main, Germany, 2 Fraunhofer Institute of Molecular Biology and Applied Ecology - Project Group Translational Medicine and Pharmacology (IME-TMP), Frankfurt am Main, Germany, 3 Smell and Taste Clinic, Department of Otorhinolaryngology, University of Dresden Medical School, Dresden, Germany

Abstract

Background and Aims: Mutations reducing the function of Na\textsubscript{v}1.7 sodium channels entail diminished pain perception and olfactory acuity, suggesting a link between nociception and olfaction at ion channel level. We hypothesized that if such link exists, it should work in both directions and gain-of-function Na\textsubscript{v}1.7 mutations known to be associated with increased pain perception should also increase olfactory acuity.

Methods: SCN9A variants were assessed known to enhance pain perception and found more frequently in the average population. Specifically, carriers of SCN9A variants rs41268673C→A (P610T; n = 14) or rs6746030C>T (R1150W; n = 21) were compared with non-carriers (n = 40). Olfactory function was quantified by assessing odor discrimination and odor identification using an established olfactory test. Nociception was assessed by measuring pain thresholds to experimental nociceptive stimuli (punctate and blunt mechanical pressure, heat, and electrical stimuli).

Results: The number of carried alleles of the non-mutated SCN9A haplotype rs41268673C/rs6746030C was significantly associated with the comparatively highest olfactory threshold (0 alleles: threshold at phenylethylthanol dilution step 12 of 16 (n = 1), 1 allele: 10.6±2.6 (n = 34), 2 alleles: 9.5±2.1 (n = 40)). The same SCN9A haplotype determined the pain threshold to blunt pressure stimuli (0 alleles: 21.1 N/m², 1 allele: 29.8±10.4 N/m², 2 alleles: 33.5±10.2 N/m²).

Conclusions: The findings established a working link between nociception and olfaction via Na\textsubscript{v}1.7 in the gain-of-function direction. Hence, together with the known reduced olfaction and pain in loss-of-function mutations, a bidirectional genetic functional association between nociception and olfaction exists at Na\textsubscript{v}1.7 level.

Introduction

Rare variants of voltage-gated sodium channels Na\textsubscript{v}1.7 [1] coded by homozygous nonsense mutations in the SCN9A gene result in truncated, non-functional sodium channels that produce ion currents no greater than background [2]. Na\textsubscript{v}1.7 channels are expressed on pain receptors and afferent nociceptive neurons [3,4]. Thus these [2] and other loss-of-function variants cause a complete [5,6] or a partial [7] insensitivity to pain. Due to its important role in pain perception and because their expression is restricted to peripheral sensory neurons [8], Nav1.7 channels are presently reckoned as a promising target for the development of new analgesics [9,10]. However, expression of Na\textsubscript{v}1.7 channels is not confined to nociceptive neurons. They are also expressed on olfactory neurons [11], where they have been shown to be the most predominant sodium channel in rodents [12]. In the absence of functional Na\textsubscript{v}1.7 channels, olfactory neurons continue to produce action potentials after excitation by odors but fail to initiate synaptic signaling [13]. Hence a common co-phenotype in patients carrying loss-of-function variants of SCN9A is anosmia [2,5,6,13], which continues to raise scientific interest in pain-focused reports [14]. This suggests a link between nociception and olfaction at ion channel level [15].

Based on the physiological function of Na\textsubscript{v}1.7, we hypothesized that this link should work in both directions. That is, gain-of-function SCN9A variants, causing severe pain attacks by enhancing channel activation or impairing channel inactivation associated with inherited primary erythromelalgia or the paroxysmal pain syndrome [16–26], should also cause enhanced olfaction. To prove the hypothesis, human carriers of more frequent SCN9A variants, i.e., rs6746030C>T (R1150W) found at an allelic frequency in caucasians of ~14%, and associated with decreased heat thresholds [27], and rs41268673C>A (P610T), found at an allelic frequency of ~4% and also modulating nociception [28], were studied for their joint nociceptive and olfactory effects.
Methods

Subjects and Design

The study followed the Declaration of Helsinki and was approved by the Ethics Committee of the Goethe-University Frankfurt am Main, Germany. Informed written consent from each participating subject had been obtained. In general, data storage and handling was performed in compliance with the data protection act of the German federal state Hessen, i.e., Hessisches Datenschutzgesetz (HDSG), and the German Federal Data Protection Act, i.e., Bundesdatenschutzgesetz (BDSG). All participants were of Caucasian ethnicity by self-assignment. Three genotypic groups were enrolled, i.e., non-carriers of the minor alleles of SCN9A rs41268673C>A (P610T) and rs6746030C>T (R1150W), and carriers of either of the minor alleles. Power calculations based on published data [29,30] had resulted in group sizes of 10 to observe differences of 15% in nociceptive thresholds [30] and of 16 to observe clinically relevant differences of 5.5 points [31] in an olfactory score, both at a power of 80% and an α error of 5%. To further increase the power, the group size for wild type subjects was roughly doubled to 40. The enrolled cohort finally consisted of 29 healthy men and 46 women (age 20–43 years, mean ± standard deviation 26.1±4.2 years) of whom 40 were wild type with respect to both SCN9A loci, 14 carried the minor rs41268673A allele and 21 the minor rs6746030T allele. The subjects actual health was assessed by medical history, physical examination including vital signs, and routine clinical laboratory test results.

Genotyping

Compared with the rare gain-of-function variants associated with pathologically syndromes of exacerbated pain episodes, the selected variants confer only moderate pain enhancing effects. However, their frequency is high enough to allow for the present controlled study investigating the link between enhanced nociception and olfaction at Na1.7 sodium channel level. The variant rs6746030C>T causes an amino acid exchange from arginine to tryptophan at position 1150 located in the intracellular loop between transmembrane domains II and III of Na1.7, a region of the channel with unknown function. Thus, the exact mechanism of the enhanced pain sensitivity is unclear. Electrophysiological assessments showed a slightly lesser voltage-dependent slow inactivation of Na1.7 1150W (encoded by the minor A allele) proposed to cause changes in the setting of the threshold and firing frequency of nociceptive neurons and thus to render the neurons more sensitive to painful stimuli [27]. Furthermore, Na1.7 1150W produced hyperexcitability when expressed in rat dorsal root ganglion neurons [22].The other variant, rs41268673C>A, causes an amino acid exchange at position 610 from proline to threonine, however, its molecular consequences are unknown yet.

DNA samples were available from 822 unrelated subjects of Caucasian ethnicity (mostly medical students) who had consented into genotyping. Ethics approval for genotyping had been obtained. Genomic DNA was extracted from 200 µl blood using the EZ1 DNA Blood 200 µl Kit on a BioRobot EZ1 Workstation (Qiagen, Hilden, Germany). Genotyping for the functional variant SC9NA rs41268673C>A and rs6746030C>T was done from genomic DNA by means of Pyrosequencing™ assays on a PSQ 96 MA System (Qiagen, Hilden, Germany) using the PyroMark Gold Q96 Reagents set (Qiagen, Hilden, Germany) in a Mastercycler ep gradient S instrument (Eppendorf, Hamburg, Germany), using the HotStar plus Taq Polymerase system (Qiagen, Hilden, Germany) and SNP-specific PCR primers (for rs41268673 forward primer: 5'-GCGACGCGACGATACAT-CAG-3' and reverse primer: 5'-biotin-TGTTAAGGTCT-TACGCTGTCA-3'; for rs6746030T: forward primer: 5'-TTTTGGAGGAAGCACAGA-3' and reverse primer: 5'-TTTTGGAGGAAGCACAGA-3'), each 14 carried the minor A allele, and rs6746030C>A (P610T) and rs6746030C>T were performed in a 25 µl assay volume on a BioRobot EZ1 Workstation (Qiagen, Hilden, Germany) and used as positive controls as previously described [32].

Assessment of Nociceptive and Olfactory Sensitivity

Olfactory testing.

The olfactory test was based on felt-tip pens that contained a solution of an odorant instead of liquid dye (“Sniffin Sticks”: Burghart, Wedel, Germany [37]). The pen’s tip was placed 1–2 cm in front of the nostrils, in the case of triplet pen presentation at an interval of approximately 3 s. Three main components of olfactory function were assessed binnarily. Specifically, odor thresholds were obtained for the rose-like odor phenylethylalcohol presented in 16 successive 1:2 dilution steps starting from a 4% solution. Using a three-alternative forced-choice task (3-AFC) and a staircase paradigm starting at low phenylethylalcohol concentrations, one pen with the odorant and two blanks were presented at each dilution step. Two successive correct or one incorrect identification triggered the reversal of the staircase. The odor threshold was the mean of the last four out of seven staircase reversals (normal values >6 [29]).

Odor discrimination was determined with 16 triplets of pens, two containing the same odorant and the third a different, “target” one (i.e., (target/non-target) butanol/2-phenyl ethanol, isoamylacetate/anethole, anethole/eugenol, limonene/fenchone, (clove/carnation) eugenol/cinnamon aldehyde, dihydrodioxo-senoxide/methanol, acetaldehyde/isoamylacetate, citronellal/finalool, pridine/limonene, limonene/citronellal, eucalyptol/ dipiryridyl, dipiryridyl/cyclopendadecanone, butanol/fenchone, octylacetate/cinnamon aldehyde, carvone/acetaldehyde). The discrimination performance was assessed employing a 3-AFC task (normal score ≥11 correct discriminations).

Finally, odor identification was determined with 16 odors (i.e., orange, leather, cinnamon, peppermint, banana, lemon, liquorice, turpenine, garlic, coffee, apple, clove, pineapple, rose, anise and fish) using a four-alternative forced-choice task with presentation of a list of four descriptors for each pen (normal score: ≥12 correct identifications).

The evaluation of olfactory performance followed the clinically established procedure consisting of calculating a composite “TDI score” (“Threshold Discrimination Identification”) as the sum of the scores from the three subtests [38]. Pathologic olfactory function is indicated by TDI ≥30.5, with the separation of
hyposmia (30.5 ≥ TDI > 15.5) from functional anosmia at TDI ≤ 15.5 [29].

**Experimental pain threshold testing.** Heat pain thresholds, as described previously [30], were obtained using a Thermal Sensory Analyzer (Medoc Advanced Medical Systems Ltd., Ramat Yishai, Israel). Heat stimuli (range 32–32.5 °C) were applied with a 3 × 3 cm² thermode placed on a skin area of the left or right (randomized) volar forearm. Temperature was continuously increased by 0.3 °C/s starting at 32 °C. The subject pressed a button at the first sensation of pain, defined as the heat pain threshold, which triggered cooling of the thermode by 10 °C/s. Heat stimuli were applied eight times at intervals of 25–35 s. The median of last five responses was used as heat pain threshold because in previous experiments a plateau was reached after the first three measurements.

**Cold pain** thresholds were determined with the same equipment as heat pain thresholds. Cold stimuli (range 32–0 °C) were applied with the 3 × 3 cm² thermode placed on a skin area of the volar forearm opposite to the side used for the determination of the heat pain threshold. Temperature was continuously lowered from 32 °C to 0 °C by 1 °C/s. Since preliminary experiments had not indicated any directed tendency of the first measurements, cold pain thresholds were measured only five times and the median of these measurements was submitted to the statistical analysis.

Pain thresholds to **electrical stimuli** were obtained using a constant current device (Neurometer® CPT, Neurotron Inc., Baltimore, MD) that delivered sine-wave stimuli at 5 Hz applied via two gold electrodes placed on the medial and lateral side of the mid-phalanx (middle finger of the right hand as default-testing site). Their intensity was increased from 0 to 20 mA by 0.2 mA/s. During the test, subjects kept a button continuously pressed until they felt pain and interrupted the current by releasing the button. The electrical current at which this occurred was defined as the pain threshold. Measurements were repeated five times at intervals of 30 s and the median was analyzed.

Pain thresholds to **blunt pressure** were obtained using a pressure algometer with a circular and flat probe of 1 cm diameter (Commander Algometer, JTECH Medical, Midvale, Utah). It was placed perpendicularly onto the mid-phalanx of the right middle finger. The pressure was increased at a rate of approximately 9 N/cm² per second until the subject indicated pain. The increase in pressure was controlled manually by the investigator and stopped once the subject reported pain. The maximum pressure applied was recorded automatically. The procedure was repeated five times at intervals of 30 s. Mechanical pain threshold to blunt pressure was the median of the five measurements.

**Statistics**

The hypothesis of the assessments was that SCN9A SNPs previously associated with high pain due to sodium Na,1.7 hyperactivity are also associated with increased olfactory acuity. Therefore, the analysis firstly aimed at identifying the SCN9A variant that modulated an olfactory parameter by submitting each olfactory parameter (odor threshold, discrimination, identification) to multiple linear regression analysis (SPSS 21 for Linux, SPSS Inc., Chicago, USA) with stepwise inclusion of SCN9A variants. As the hypothesis was directed, i.e., higher sensitivity was the expected effect of the variants [22], post-hoc tests were one-sided using the Jonckheere–Terpstra trend test as a gene dose effect was expected. The same test was applied subsequently to identify whether the SCN9A variant identified as modulating olfaction also modulated pain. The z-level was set at 0.05 and corrected for multiple testing (Bonferroni) when indicated.

**Results**

In the random sample of 822 subjects screened for this study, the observed minor allelic frequencies were 3.6% for variant rs41268673C>A and 14% for rs6746030C>T; Hardy-Weinberg equilibrium was preserved (χ² test: p = 0.03). Further analyses were done in the study cohort of 75 subjects selected for SCN9A genotypes. Linkage disequilibrium parameters between the two SCN9A SNPs were D’ = 100 and of r² = 0.7 and both SNPs were located together in a haplобlock. Therefore, association analyses focused on haplotypes. The non-mutated haplotype rs41268673C/rs6746030C was found at an allelic frequency of 75.7% (and in the random sample of n = 822 it had a frequency of 82.5%), the haplotype with major allele of the rs41268673 SNP and variant (minor) allele of the rs6746030SNP, i.e., rs41268673C/rs6746030T, was found at an allelic frequency of 13.8%, and the haplotype with variant allele of the rs41268673 SNP and major allele of the rs6746030 SNP, i.e., rs41268673A/rs6746030C, had an allelic frequency of 10.5%. A haplotype with both minor alleles was not found.

None of the subjects reported any perception of pain or smell sensitivities differing from the normal status. Most subjects (n = 72) were normosmic (TDI score ≥ 30.5) [29]. Among the three hyposmic subjects (TDI of 28, 29 and 30, respectively), the wild type haplotype rs41268673C/rs6746030C was carried in a total of five copies. Multiple linear regression analysis of olfactory parameters identified the SCN9A wild-type haplotype as the genetic factor that significantly influenced olfactory thresholds (p = 0.024). An increasing number of non-mutated haplotype alleles was associated with a higher threshold, i.e., with the detection limit of volatile phenylethylethanol at lower dilutions (Figure 1). This was reflected in a statistically significant trend (Jonckheere’s trend test p = 0.013 one-sided). The same wild-type haplotype also modulated the pressure pain threshold (Jonckheere’s trend test p = 0.033 one-sided). In addition, pressure pain thresholds were significantly modulated by the rs41268673A/rs6746030C haplotype (p = 0.022) in the expected direction of carriers having lower thresholds than wild-type subjects.

The remaining olfactory parameters and pain thresholds to heat and punctate mechanical stimuli differed only insignificantly between the identified haplotypes, but still observed variations displayed a tendency in the hypothesized direction. Specifically, the composite olfactory TDI scores dwindled with each additional wild-type haplotype from a value of 40 in the carrier of zero wild-type haplotypes (n = 1), to 37±3.4 in carriers of one wild-type haplotype (n = 34), to 35±3.2 in carriers of two wild-type haplotypes (n = 40). Likewise, the heat and cold pain threshold tended in the direction expected from animal experiments [39], i.e., the heat pain threshold was lower while the cold pain threshold was higher in carriers of one wild-type haplotype (45.5±3.3 °C and 13.1±9.6, respectively; n = 34) compared to carriers of two wild-type haplotypes (46.5±2.2 °C and 9.9±9.3 °C, respectively; n = 40).

**Discussion**

The study hypothesis that SCN9A gain-of-function variants should cause increased olfactory acuity as SCN9A loss-of-function variants induce anosmia, was verified by inverse concluding that the presence of wild-type genetics was associated with the opposite effects, i.e., reduced pain perception and olfactory acuity. This way we verified that there is a robust link between nociceptive and olfactory acuities at Na,1.7 ion channel level [15] and that this link works in both directions, rather than in the already known negative direction of sensory function loss [2,5,6].
The presence of SCN9A both sensory thresholds increase in the same direction indicating that rs41268673C/rs6746030C. Please note that the olfactory threshold doi:10.1371/journal.pone.0068654.g001

Figure 1. Olfactory and pressure pain thresholds increased with increasing number of wild-type SCN9A haplotype alleles rs41268673C/rs6746030C. Please note that the olfactory threshold to phenylethyl ethanol is scaled inversely as the ordinate indicates dilution steps, with higher numbers denoting lower thresholds. Thus, both sensory thresholds increase in the same direction indicating that the presence of SCN9A variants lowers the thresholds making the subject more sensitive against smell and pain stimuli. Single data and the median (thick horizontal red line) are shown. Significant genotype effects were also found when excluding group zero. doi:10.1371/journal.pone.0068654.g001

Although patients with hereditary channelopathy-associated insensitivity to pain due to SCN9A channelopathy [40] were reported to be otherwise healthy except anosmia [2], pathophysiological implications of SCN9A are not limited to pain and olfaction [41,42]. Gustation may be another sense affected by functional changes in the Na1.7 sodium channels. In particular, SCN9A, together with SCN2A and SCN3A, was found in cells expressing TRPM5, which is attributed to the initial sodium influx in sweet, bitter, and umami taste cells [43]. There it is likely to account for the tetrodotoxin-sensitive sodium currents [43]. Recently, a new SCN9A missense variant (G2567A leading to an amino acid exchange from glycine to aspartic acid at position 856) has been linked to abnormal limb development in three male family members reporting crythema and burning pain in their distal extremities [44]. Further associations have been shown with the hereditary generalized epilepsy with febrile seizures [45] and with other hereditary epilepsy phenotypes [45,46]. Outside the nervous system, Na1.7 plays a role in cell migration, endocytosis, and secretion during progression of aortic intimal hyperplasia [47]. SCN9A is also expressed in human prostate cancer [48,49], for which it has been proposed as a biomarker [50]. Thus, there are plenty of other physiological systems and functions than pain and olfaction that are likely to be affected by functional SCN9A variants.

Neither are pathophysiological consequences associated with SCN9A restricted to nociception and olfaction, nor is the link between pain and smell perception restricted to SCN9A. Indeed, these two evolutionarily ancient sensory systems [51,52] share more common features on the molecular level. For example, the cannabinoid system not only plays an important role in nociception [53], but cannabinoids like 2-arachidonoyl-glycerol are also synthesized in olfactory receptor neurons of Xenopus laevis larvae. There, they control odor detection thresholds via cannabinoid receptor activation [54]. Also transient receptor potential cation channel, subfamily V, member 1, activated by heat, protons and capsaicin are expressed at nociceptors, pain relevant brain areas [55] and also in the olfactory bulb [56].

Odor thresholds have been reported to be unrelated to higher cognitive factors, whereas proficiency in executive functioning and semantic memory contributed significantly to odor discrimination and identification performance [57]. Since only olfactory thresholds were presently increased, while discrimination and identification remained unaffected, this supports a more peripherally than centrally localized effect of increased Na1.7 function. The same applies for the increased nociception. Only recently it has been shown that small nerve fiber neuropathy is caused by the expression of gain of function mutant sodium channels in small diameter peripheral axons [58]. This would be consistent with the reported predominant localization of Na1.7 channels, which are preferentially expressed within dorsal root ganglion neurons and their small-diameter peripheral axons [59].

The present results establish olfactory effects as a class effect of future Na1.7 modulating analgesics [9,10]. Olfactory side effects seem unavoidable, as opposed to other side effects, such as cardiovascular side effects. The latter seem to be owed to an insufficient specificity for Na1.7, e.g. benzazepines binding at Na1,5 [60] that is expressed on the cardiac muscle [61]. Although this might be a disadvantage for future analgesics, when thinking in the opposite direction, Na1.7 activation may be suitable as a cure for remnant olfactory function. However, at this point, this assumption is purely speculative. This is amongst other things because the exact mechanism of hyposmia, for instance, in patients with post-viral olfactory loss or patients with sinusosal disease, is often unclear. While olfactory receptor neurons (ORN) are still present they appear to be deformed or some of their cilia may be lost in post-viral olfactory loss [62]. ORNs appear to be normal in sinusosal disease and the olfactory disorder seems to originate from functional changes at cellular level [63]. Even in patients with posttraumatic olfactory loss it is uncertain whether shearing of the olfactory fiber is the major contributor to olfactory loss [64] or whether it results from actual brain damage. Moreover, the success of a Na1.7 activating drug as a cure for remnant olfactory function will depend on its therapeutic range and its nociceptive side effects. Achieved olfactory effects would have to be greater than those presently observed. In fact, at least 5.5 points difference in the composite TDI score are required for a perceived change of olfactory function [31]. While systemic nociceptive side effects may be avoided by a local intranasal administration, the possibility of local painful side effects due to Na1.7 activation on nociceptors still exists. Taken together, the utility of Na1.7 modulating agents as a cure for olfactory disorders remains uncertain. Nevertheless, it is worth assessing as there is a need for such drugs. Olfactory loss...
in otherwise healthy people causes suffering, as it is associated with a reduction in the enjoyment of food [65], will impact the quality of life and may greatly affect certain professionals who rely on their sense of smell. Cures, on the other hand, are rare [66] and restricted to a few agents with local decongestive or anti-inflammatory activity such as metazoline [67] or corticosteroids [68] and further substances such as the N-methyl-D-aspartic acid antagonist caroverine [69] or the phosphodiesterase inhibitor theophylline [70].

Present results verified the hypothesis that there is a link between nociception and olfaction at Nav1.7 sodium channel level in the gain-of-function direction, adding to the previously known opposite effects of loss-of-function mutations in the SCN9A gene and hence, establishing that the link is bidirectional. A wild-type SCN9A haplotype composed of rs41268673C/rs6746030C alleles was identified to be linked with a comparatively reduced pain perception and olfaction acuity. This haplotype is frequent and found in a random sample of Caucasians at an allelic frequency of 82.5%. It is one of the few human genetic variants modulating olfactory function. However, as often seen with frequent genetic variants [71], it confers only a small effect size resulting in a measurable although not yet perceivable change in olfaction without pathologic enhancement of nociception. From a pharmacological point of view, the results indicate that modulation of Na+,1.7 may serve different clinical purposes. This includes alleviation for the treatment of pain but also activation as a cue of diminished olfaction for which a medical need exists [66]. Nevertheless, pharmacological modulation of Na+,1.7 function will always be associated with nociceptive and olfactory effects in both directions.

**Author Contributions**

Conceived and designed the experiments: JL TH BGO AD. Performed the experiments: DH BGO. Analyzed the data: JL. Wrote the paper: JL AD BGO.

**References**

1. Klugbauer N, Lacinova L, Fickerzi V, Hofmann F (1995) Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J 14: 1084–1090.
2. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, et al. (2006) An SCN9A channelopathy causes congenital inability to experience pain. Nature 444: 894–898.
3. Sangameswaran L, Fish LM, Koch BD, Rabbet DK, Delgado SG, et al. (1997) A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia. J Biol Chem 272: 14805–14809.
4. Black JA, Frezel N, Dib-Hajj SD, Waxman SG (2012) Expansion of Nav.1.7 in DRG neurons extends from peripheral terminals in the skin to central pretreminal branches and terminals in the dorsal horn. Mol Pain 8: 82.
5. Nilsen KB, Nicholas AK, Woods CG, Mellgren SI, Nebuchzahl E, et al. (2005) Two novel SCN9A mutations causing insensitivity to pain. Pain 145: 155–158.
6. Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, et al. (2007) Loss-of-function mutations in the Nav.1.7 gene underlie congenital insensitivity to pain in multiple human populations. Clin Genet 71: 311–319.
7. Staud R, Price DD, Janicke D, Andrade E, Hadjipanayis AG, et al. (2010) Two novel mutations of SCN9A (Nav.1.7) are associated with partial congenital insensitivity to pain. Eur J Pain.
8. Toledo-Aral JJ, Moss BL, He ZJ, Koszowski AG, Whisenand T, et al. (1997) Erythermalgia: a gain-of-function mutation in Nav.1.7. Ann Neurol 59: 553–558.
9. Estacion M, Harry TP, Chui JS, Tyrrell L, Dib-Hajj SD, et al. (2009) A sodium channel gene SCN9A polymorphism that increases nociceptor excitability. Annuals of Neurology 66: 862–866.
10. Cregg R, Momin A, Rugiero F, Wood JN, Zhao J (2010) Pain channelopathies. J Med Genet 47: 1–9.
11. Cregg R, Laguda B, Werdehausen R, Cox JJ, Liney JE, et al. (2013) Novel Mutations Mapping to the Fourth Sodium Channel Domain of Nav.1.7 Result in Variable Clinical Manifestations of Primary Erythromelalgia. Neuroscientific Med.
12. Wu MT, Huang PY, Yen CT, Chen CC, Lee MJ (2013) A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers. PLoS One 8: e55212.
13. Klein CJ, Wu Y, Kallioyle JL, Sanoson P, Davis MD, et al. (2013) Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia. J Neurol Neurosurg Psychiatry 84: 386–391.
14. Estacion M, Dib-Hajj SD, Beuke PJ, Te Morsche RH, Eastman EM, et al. (2000) Nav.1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci 20: 11079–11088.
15. Reimann F, Cox JJ, Beller I, Dratschenko L, Zaykin DV, et al. (2010) Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci U S A 107: 5148–5153.
16. Samuels ME, te Morsche RH, Lynch ME, Drent WJ (2008) Compound heterozygosity in sodium channel Nav.1.7 in a family with hereditary erythromelalgia. Mol Pain 4: 21.
17. Hummel T, Kobal G, Guzdziol H, Mackay-Sim A (2007) Normative data for the “Sniffin’ Sticks” including tests of odor identification, odor discrimination, and olfactory thresholds: an up-date based on a group of more than 3,000 subjects. Eur Arch Otorhinolaryngol 264: 257–261.
18. Neddermeyer TJ, Fihler K, Lotoch J (2008) Principal components analysis of pain thresholds to thermal, electrical, and mechanical stimuli suggests a predominant common source of variance. Pain 130: 286–291.
19. Guzdziol V, Loteck H, Nahmer A, Zahnert T, Hummel T (2006) Clinical significance of results from olfactory testing. Laryngoscope 116: 1856–1863.
20. Doehring A, Kirkhof A, Lotoch J (2009) Genetic diagnostics of functional variants of the human dopamine D2 receptor gene. Psychiatr Genet 19: 259–260.
21. Levontin RC (1964) The Interaction of Selection and Linkage. I. General Considerations; Heterotic Models. Genetics 49: 49–67.
22. Gout BS, Long AD (2003) The loadown on linkage disequilibrium. Plant Cell 15: 1502–1506.
23. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
24. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 988–992.
25. Hummel T, Sekinger B, Wolf S, Pauli E, Kobal G (1997) “Sniffin’ Sticks”: Olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 22: 39–52.
26. Wolfensberger M, Schnieter I, Wellig-Lussen A (2000) Sniffin’Sticks: a new olfactory test battery. Acta Otolaryngol 120: 303–306.
27. Minett MS, Nassar MA, Clark AK, Passmore G, Dickinson AH, et al. (2012) Distinct Nav.1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat Commun 3: 791.
28. Young EE, Larriew W, Beller I (2012) Genetic basis of pain variability: recent advances. J Med Genet 49: 1–9.
Enhanced Olfaction Associated with SCN9A

41. Drenth JP, Waxman SG (2007) Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest 117: 3603–3609.
42. Dib-Hajj SD, Yang Y, Black JA, Waxman SG (2013) The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci 14: 49–62.
43. Gao N, Lu M, Echeverri F, Lai B, Kalabat D, et al. (2009) Voltage-gated sodium channels in taste bud cells. BMC Neurosci 10: 20.
44. Hoeijmakers JG, Merkies IS, Gerrits MM, Waxman SG, Faber CG (2012) Genetic aspects of sodium channels pathology in small fiber neuropathy. Clin Genet 82: 351–358.
45. Singh NA, Pappas C, Dahle EJ, Claes LR, Preuss TH, et al. (2009) A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet 5: e1000649.
46. Guerini R, Cellini E, Mei D, Meintier T, Petrelli C, et al. (2010) Variable epilepsy phenotypes associated with a familial intragenic deletion of the SCN1A gene. Epilepsia 51: 2474–2477.
47. Meguro K, Iida H, Takano H, Morita T, Sata M, et al. (2009) Function and role of voltage-gated sodium channel NaV1.7 expressed in aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 296: H211–219.
48. Diss JK, Fraser SP, Walker MM, Patel A, Latchman DS, et al. (2008) Beta-subunits of voltage-gated sodium channels in human prostate cancer: quantitative in vitro and in vivo analyses of mRNA expression. Prostate Cancer Prostatic Dis 11: 325–333.
49. Uysal-Onganer P, Djamous MB (2007) Epidermal growth factor potentiates distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res 135: 162–168.
50. Diss JK, Stewart D, Pani F, Foster CS, Walker MM, et al. (2005) A potential modifier of Dravet syndrome. PLoS Genet 1: e1000054.
51. Benton R (2009) Molecular basis of odor detection in insects. Annals of the New York Academy of Sciences 1170: 478–481.
52. Kang K, Pulver SR, Panzano VC, Chang EC, Griffith LC, et al. (2010) Analysis of Drosophila TRPA1 reveals an ancient origin for human chemical nociception. Nature 464: 597–600.
53. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, et al. (2007) Cannabinoids modulate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10: 870–879.
54. Breugel K, Manzini I, Pucetelli F, Gutermann B, Di Marzo V, et al. (2010) The endocannabinoid 2-arachidonoylglycerol controls odor sensitivity in larvae of Xenopus laevis. J Neurosci 30: 8963–8973.
55. Steenland HW, Ko SW, Wu LJ, Zhao M (2006) Hot receptors in the brain. Mol Pain 2: 34.
56. Toth A, Boczan J, Kedel N, Lianecz E, Bagi Z, et al. (2005) Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res 135: 162–168.
57. Hedner M, Larsson M, Arnold N, Zucco GM, Hummel T (2010) Cognitive factors in odor detection, odor discrimination, and odor identification tasks. J Clin Exp Neuropsychol 32: 1062–1067.
58. Faber CG, Hoeijmakers JG, Ahn HS, Cheng X, Han C, et al. (2012) Gain of function Naun1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 71: 26–39.
59. Han C, Hoeijmakers JG, Ahn HS, Zhao P, Shah P, et al. (2012) NaV1.7-related small fiber neuropathy: impaired slow-inactivation and DRG neuron hyperexcitability. Neurology 78: 1635–1643.
60. Williams BS, Friks JP, Priest ET, Brocha RM, Dai K, et al. (2007) Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry 46: 14693–14703.
61. Thiele JW, Cummins TR (2011) Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front Pharmacol 2: 54.
62. Yamaqishi M, Fujiwara M, Nakamura H (1994) Olfactory mucosal findings and clinical course in patients with olfactory disorders following upper respiratory viral infection. Rhinology 32: 113–118.
63. Raviv JR, Kern RC (2004) Chronic sinusitis and olfactory dysfunction. Otolaryng Clin North Am 37: 1143–1157, v–vi.
64. Yamaqishi M, Okazoe R, Ishizuka Y (1994) Olfactory mucosa of patients with olfactory disturbance following head trauma. Ann Otol Rhinol Laryngol 103: 279–284.
65. Hummel T, Nordin S (2005) Olfactory disorders and their consequences for quality of life. Acta Oto-Laryngologica 125: 116–121.
66. Lorch J, Geisslinger G, Hummel T (2012) Sniffing out pharmacology: interactions of drugs with human olfaction. Trends Pharmacol Sci 33: 193–199.
67. Hummel T, Rosthauer C, Pauli E, Kabol G (1998) Effects of the nasal decongestant oxymetazoline on human olfactory and intranasal trigeminal function in acute rhinitis. European journal of clinical pharmacology 54: 521–528.
68. Toth J, Tenmell AF (2004) [Drug therapy for disturbances of smelling]. Laryngorhinootologie 83: 124–134.
69. Quint G, Tenmell AF, Hummel T, Ehrenberger K (2002) The quinolizidine derivative caroverine in the treatment of sensorineural smell disorders: a proof-of-concept study. Acta oto-laryngologica 122: 877–881.
70. Henkin RJ, Velcu I, Schmidt L (2011) Relative resistance to oral theophylline treatment in patients with hyposmia manifested by decreased secretion of nasal mucus cyclic nucleotides. Am J Med Sci 341: 17–22.
71. Doehring A, Kusener N, Führ K, Nedderneyer TJ, Schneider G, et al. (2011) Effect sizes in experimental pain produced by gender, genetic variants and sensitization procedures. PloS one 6: e17724.